Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 7/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 7/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 16/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.59 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.52 |
| ▸ | CHRNG | P07510 | 2/20 | 0.52 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.52 |
| ▸ | CHRND | Q07001 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118728 | 1.00 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL13916010 | 1.00 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Hydrochloric Acid SCHEMBL1972897 | 0.97 | CHRNB4 (0.95) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| Hydrochloric Acid SCHEMBL29988071 | 0.97 | CHRNB4 (0.95) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL11538560 | 0.84 | CHRNB4 (0.72) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2061331 | 0.84 | CHRNB4 (0.73) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL11543466 | 0.83 | CHRNB4 (0.69) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL11932910 | 0.81 | CHRNB4 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL5559162 | 0.75 | CHRNB2 (1.00) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL5552804 | 0.75 | CHRNB2 (1.00) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-3717488-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | Dart NeuroScience, LLC (US) | 2020-10-07 | — | — | EP | claimed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | claimed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | claimed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | claimed |
| EP-2204369-A1 | Process for preparing varenicline and intermediates for use therein | Medichem, S.A. (ES) | 2010-07-07 | — | — | EP | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20020193360-A1 | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | PFIZER INC. | 2002-12-19 | — | — | US | claimed |
| US-20020016334-A1 | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | COE JOTHAM WADSWORTH (US) | 2002-02-07 | — | — | US | claimed |
| EP-1177798-A2 | A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-20020010192-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC. | 2002-01-24 | — | — | US | claimed |
| EP-1159970-A2 | A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent | Pfizer Products Inc. (US) | 2001-12-05 | — | — | EP | claimed |
| EP-1150715-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| US-20010036943-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| US-20010036949-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| EP-1078637-A2 | Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CHRNB4 296/4885CHRNA3 178/4885CHRNB2 114/4885 |
| US-20020016334-A1 | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | CHRNB4, CHRNA10, CHRNA7 | CHRNB4 1/4885CHRNA3 12/4885CHRNB2 7/4885 |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CHRNB4 296/4885CHRNA3 178/4885CHRNB2 114/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNB4 20/4885CHRNA3 7/4885CHRNB2 19/4885 |
| US-20020193360-A1 | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | CHRNE, CHRNA10, GABRE | CHRNB4 11/4885CHRNA3 17/4885CHRNB2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.